Cambridge, Massachusetts-based Biogen Inc. ( BIIB) discovers, develops, manufactures, and delivers therapies for treating ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

In a filing Friday, it said how many of those cut are Massachusetts ... Biogen had also applied to market it as a treatment for. In its recent third-quarter earnings call, Sage said the two ...

Biogen, Inc. is a biopharmaceutical company ... and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better. Based in Cambridge, MA, Biogen Inc. is one of the world’s leading biotechnology companies, which focuses on ...

Biogen Inc. (NASDAQ:BIIB) the central nervous system disease drug developer based in Cambridge Massachusetts, reported its Q3 earnings yesterday, Wednesday, October 30. First, let's look at some ...

Biogen is the latest big biotech to make a play in protein degradation. The Massachusetts-based company has announced a deal to use Neomorph’s molecular glue degrader discovery platform to go ...

the Cambridge, Massachusetts-based company said Wednesday in a statement. While that’s a 6% decline from a year earlier, it beat analysts’ estimates. The results could help Biogen start to ...

Biogen, headquartered in Cambridge, Massachusetts, has established itself as a key player in the biopharmaceutical industry, focusing on innovative therapies for neurological conditions.

Ahead of reporting its third-quarter earnings on Wednesday, Biogen Inc. is making some changes to its leadership team. Ahead of reporting its third-quarter earnings on Wednesday, Biogen Inc. is ...